Explanation  China's State Drug Administration recently approved its first domestic listing application for a dual-valent human papillomavirus vaccine, known as Xin Ke Ning, which means China has become the third country in the world to successfully develop and produce HPV vaccines after the US and the UK.
HPV is the abbreviation of human papillomavirus.% of cervical cancer is caused by HPV infection. the domestic hpv vaccine was jointly developed by china national infectious disease diagnostic reagent and vaccine engineering technology research center (xia ning shao team of xiamen university) and xiamen wantai, using a vaccine production system based on e. coli, with fully autonomous intellectual property rights, suitable for women aged 9 to 45. Zhang Jun, deputy director of the research center, said in an interview with China News Agency reporters that it took about 18 years from project development to listing today.
We have adopted an independent new vaccine production system, this is to say that our own laboratory in the development of hepatitis e vaccine has had a preliminary successful experience, and then we expand to cervical cancer vaccine, and this road because they have never tried to succeed abroad, so in this (research) process is also a lot of aspects of this, cannot say that at least we need to be more solid scientific data to convince everyone.
Unlike generic drug shortcuts, the original system can only start from scratch, with many difficulties. Over the past 18 years, at least 2,000 people have been involved in the development of domestic HPV vaccines, from blue to white hair, after thousands of experiments to overcome many technical difficulties.